Ruut Laitio, Marja Hynninen, Olli Arola, Sami Virtanen, Riitta Parkkola, Jani Saunavaara, Risto O Roine, Juha Grönlund, Emmi Ylikoski, Johanna Wennervirta, Minna Bäcklund, Päivi Silvasti, Eija Nukarinen, Marjaana Tiainen, Antti Saraste, Mikko Pietilä, Juhani Airaksinen, Leena Valanne, Juha Martola, Heli Silvennoinen, Harry Scheinin, Veli-Pekka Harjola, Jussi Niiranen, Kirsi Korpi, Marjut Varpula, Outi Inkinen, Klaus T Olkkola, Mervyn Maze, Tero Vahlberg, Timo Laitio
IMPORTANCE: Evidence from preclinical models indicates that xenon gas can prevent the development of cerebral damage after acute global hypoxic-ischemic brain injury but, thus far, these putative neuroprotective properties have not been reported in human studies. OBJECTIVE: To determine the effect of inhaled xenon on ischemic white matter damage assessed with magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: A randomized single-blind phase 2 clinical drug trial conducted between August 2009 and March 2015 at 2 multipurpose intensive care units in Finland...
March 15, 2016: JAMA: the Journal of the American Medical Association